Kubo N
Department of Clinical Laboratory, Omiya Medical Center, Jichi Medical School.
Rinsho Byori. 1994 Nov;42(11):1119-27.
Lipoprotein(a) (Lp(a)) is generally regarded as an atherogenic lipoprotein because so much previous cross-sectional research has shown a tight connection between its plasma level and development of atherosclerosis. Previous studies on Lp(a) concerning its localization in atherosclerotic lesions and the clinical usefulness of serum level determination were reviewed, and the role of Lp(a) in the progression of atherosclerosis was discussed. In addition to its experimental and biophysiological relevance, clinicoepidemiological and socioeconomical consideration is becoming necessary for the clinicopathologist to evaluate the usefulness of blood Lp(a) measurement. In the clinicopathological field, much interest has been concentrated on the standardization of Lp(a) measurement because many methods have previously been applied to measure the blood Lp(a) concentration, and many problems concerning Lp(a) measurement have been raised. Future results from randomized or cohort studies in Japanese populations on Lp(a) will provide firmer evidence for the clinical usefulness of Lp(a) measurement.
脂蛋白(a)（Lp(a)）通常被视为一种致动脉粥样硬化的脂蛋白，因为此前大量的横断面研究表明其血浆水平与动脉粥样硬化的发展之间存在紧密联系。本文回顾了此前关于Lp(a)在动脉粥样硬化病变中的定位以及血清水平测定的临床实用性的研究，并讨论了Lp(a)在动脉粥样硬化进展中的作用。除了其实验和生物物理相关性外，临床病理学家评估血液Lp(a)测量的实用性时，临床流行病学和社会经济方面的考虑也变得必要。在临床病理领域，人们对Lp(a)测量的标准化给予了极大关注，因为此前有许多方法被用于测量血液Lp(a)浓度，并且出现了许多与Lp(a)测量有关的问题。未来日本人群关于Lp(a)的随机或队列研究结果将为Lp(a)测量的临床实用性提供更确凿的证据。
